Latest news on Laboratorytalk categorised by product type
Antibodies
Archive page 4 of 8
Our RSS feed for Antibodies press releases
Notice of allowance for US Lentivector patent
Oxford BioMedica, a gene therapy company, has received a Notice of Allowance from the US Patent Office for a Patent covering modifications to lentiviral vectors that improve safety and efficacy
News from Oxford BioMedica (24 July 2006)
Lentivector is the 'system of choice' for RNAI
Paper in Nature Medicine demonstrates efficacy of Oxford BioMedica's LentiVector technology in an animal model of inherited (familial) amyotrophic lateral sclerosis (ALS) or motor neuron disease
News from Oxford BioMedica (24 July 2006)
Progress in avian transgenics biomanufacturing
Oxford BioMedica, a gene therapy company, has announced progress in the programme of its collaborative partner Viragen
News from Oxford BioMedica (24 July 2006)
Grant for Monudin from motor neurone association
The UK Motor Neurone Disease (MND) Association has awarded Oxford BioMedica a grant to support preclinical evaluation of Monudin for the treatment of Amyotrophic Lateral Sclerosis (ALS)
News from Oxford BioMedica (20 July 2006)
Key lentivector patents in China
Oxford BioMedicareports that the Patent Office of the Peoples' Republic of China has granted two patents to the company that have broad claims covering vectors derived from lentiviruses
News from Oxford BioMedica (20 July 2006)
Lentivector licensing agreement with Pfizer
Oxford BioMedica, a gene therapy company, has signed a licence agreement for its LentiVector technology with Pfizer
News from Oxford BioMedica (20 July 2006)
Report of avian transgenic milestone
Oxford BioMedica, Viragen, and the Roslin Institute (Scotland) today announced a breakthrough in their collaborative project to develop avian transgenic biomanufacturing
News from Oxford BioMedica (20 July 2006)
European patent for Trovax covering 5T4 tumour
He European Patent Office has granted a key patent (No EP1036091), that provides broad protection for Oxford BioMedica's lead product, TroVax
News from Oxford BioMedica (20 July 2006)
More kinase assay kits for drug discovery
Serologicals says that Upstate Group, its wholly owned subsidiary, has expanded its Kinease FP product line to include each of the 80 individual kinases that have been validated in the assay
News from Chemicon International (19 July 2006)
More cost efficient Western blotting detection
Serologicals announced that Upstate, its subsidiary, has released a new, more cost efficient Western blotting detection kit based on its high quality Visualizer western blot detection kit
News from Chemicon International (19 July 2006)
Commercialising human stem cell technology
Chemicon International Enters into a license to commercialise research products utilising human embryonic stem cell technology from Wisconsin Alumni Research Foundation (Warf)
News from Chemicon International (19 July 2006)
Antibody therapy for treatment of solid tumours
Oxford Biomedica announces presentation by Wyeth Pharmaceuticals of preclinical efficacy data with antibody-targeted therapy for cancer
News from Oxford BioMedica (18 July 2006)
Phase II results with Metxia in pancreatic cancer
Oxford BioMedica announced that a clinician at the Royal Liverpool University Hospital, UK, presented further data from the first stage of the Phase II trial of MetXia in pancreatic cancer
News from Oxford BioMedica (18 July 2006)
Encouraging Phase II results in renal carcinoma
The data show that TroVax is safe and well tolerated in this patient group and that the product induces a strong anti-tumour immune response against the 5T4 tumour antigen
News from Oxford BioMedica (18 July 2006)
Successful Phase II trial in pancreatic cancer
Oxford BioMedica announced that the first stage of its Phase II trial in pancreatic cancer with MetXia, the company's gene targeted prodrug activation product, has been successfully completed
News from Oxford BioMedica (18 July 2006)
Patent allowance extends Trovax protection in USA
Oxford BioMedica reports that the US Patent and Trademark Office has issued a Notice of Allowance for a key patent application, which extends the protection of TroVax, its lead cancer vaccine
News from Oxford BioMedica (14 July 2006)
Phase II trial with Trovax in renal cell carcinoma
Oxford BioMedica reports that the first patient has been treated in a second Phase II trial with TroVax in combination with interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (RCC)
News from Oxford BioMedica (14 July 2006)
Innurex nerve regeneration programme highlighted
Oxford BioMedica repots that its Innurex programme for treating spinal cord injury was highlighted in a briefing at the Science Media Centre in London for the Applied Genomics Link programme
News from Oxford BioMedica (14 July 2006)
Lentivector licensing agreement signed
Oxford BioMedica has signed its seventh licence agreement for its LentiVector technology with a Fortune 500 global biopharmaceutical company
News from Oxford BioMedica (14 July 2006)
License to use RheoSwitch
Chemicon and RheoGene sign license to use RheoSwitch and related technologies within Chemicon's research product lines focused on specialty research markets, including stem cell biology portfolio
News from Chemicon International (14 July 2006)
Earlier news from this category...
Latest news from this category...
